Neurological Complications of Antipsychotic Drugs

Schizophrenia: Third Edition

Volumn , Issue , 2011, Pages 561-576

  Haddad, Peter M ^a   Mattay, Venkata S ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Adverse effects; Antipsychotics; Cerebrovascular events; Clozapine; Extrapyramidal symptoms; Neuroleptic malignant syndrome; Seizures; Tolerability

Indexed keywords

EID: 84871251104     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444327298.ch27     Document Type: Chapter

References (142)

1. Adityanjee&Estrera A.B.(1996) Successful treatment of tardive dystonia with clozapine. Biological Psychiatry 39 , 1064-1065.
2. Adityanjee, Sajatovic, M.&Munshi, K.R.(2005) Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clinical Neuropharmacology 28, 197-204.
3. Adler, L., Angrist, B., Reiter, S.&Rotrosen, J.(1989) Neuroleptic - induced akathisia: a review. Psychopharmacology 97, 1-11.
4. American Psychiatric Association(1997) American Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia. American Journal of Psychiatry 154(Suppl.), 1-63.
5. Ananth, J., Parameswaran, S., Gunatilake, S., Burgoyne, K.&Sidhom, T.(2004) Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry 65 , 464-470.
6. Anton-Stephens, D.(1953) Preliminary observations on the psychiatric use of chlorpromazine. Journal of Mental Science 100 , 543-547.
7. Ayd, F.(1961) A survey of drug-induced extrapyramidal reactions . Journal of the American Medical Association 175 , 1054-1060.
8. Bagnall, A.M., Jones, L, Ginnelly, L. et al( 2003) A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessessment 7, 1-193.
9. Bai, Y.M., Yu, S.C.&Lin, C.C.(2003) Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 64 , 1342-1348.
10. Bailey, L., Maxwell, S.&Brandabur, M.(1997) Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1027 patients. Psychopharmacological Bulletin 33, 177-181.
11. Baldessarini, R., Cole J., Davis, J. et al.(1980) Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. American Journal of Psychiatry 137, 1163-1172.
12. Baldessarini, R., Cohen, B.&Teicher, M.(1988) Signifi cance of neuroleptic dose and plasma level in pharmacological treatment of psychosis. Archives of General Psychiatry 45 , 79-91.
13. Barnes, T.&Braude, W.(1985) Akathisia variants and tardive dyskinesia. Archives of General Psychiatry 42, 874-878.
14. Bassitt, D.P.&Louza Neto, M.R.(1998) Clozapine effi cacy in tardive dyskinesia in schizophrenic patients. European Archives of Psychiatry Clinical Neuroscience 248, 209-211.
15. Bersani, G., Grispini, A., Marini, S. et al.(1990) 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double - blind comparison with orphenadrine and placebo. Clinical Neuropharmacology 13, 125-137.
16. Bleuler, E.(1950) Dementia Praecox or the Group of Schizophrenias . New York: International Universities Press. Bottlender, R., Jager, M., Hofschuster, E., Dobmeier, P.&Moller , H.J.(2002) Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry 35, 119-121.
17. Boyer, W., Bakalar, N.&Lake, C.(1989) Anticholinergic prophylaxis of acute haloperidol-induced dystonic reactions. Journal of Clinical Psychopharmacology 7, 164-166.
18. Brooks, D.(1991) Detection of preclinical Parkinson's disease with PET. Neurology 41(Suppl. 2), 24-27.
19. Brooks, D.J.(1993) Functional imaging in relation to parkinsonian syndromes. Journal of Neurological Science 115, 1-17.
20. Burke, R.E., Fahn, S.&Jankovic, J.(1982) Tardive dystonia: late - onset and persistent dystonia caused by antipsychotic drugs. Neurology 32, 1335-1346.
21. Caroff, S.N.(1980) The neuroleptic malignant syndrome ome. J ournal of Clinics in Psychiatry 41, 79-83.
22. Caroff, S.N.&Mann, S.C.(1993) Neuroleptic malignant syndrome . Medical Clinics of North America 77, 185-202
23. Casey, D.(1981) The differential diagnosis of tardive dyskinesia. Acta Psychiatrica Scandinavica 63(Suppl. 291), 71-87.
24. Casey, D.(1985) Spontaneous and tardive dyskinesias: clinical and laboratory studies. Journal of Clincal Psychiatry 46, 42-47.
25. Casey, D.(1991) Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophrenia Research 4 , 109-120.
26. Casey, D.(1995) Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Hirsch, S.R.&Weinberger , D.R., eds. Schizophrenia . Oxford: Blackwell Science, pp. 546-565.
27. Casey, D.(1997) The relationship of pharmacology to side effects. Journal of Clinical Psychiatry 58(Suppl. 10), 55-62.
28. Casey, D.(1999) Tardive dyskinesia and atypical antipsychotic drugs. Schizophrenia Research 35, S61-S66.
29. Casey, D.&Gerlach, J.(1986) Tardive dyskinesia: what is the long-term outcome? In: Casey, D.&Gardos, G., eds. Tardive Dyskinesia and Neuroleptics: From Dogma to Reason . Washington, DC: American Psychiatric Press, pp. 76-97.
30. Casey, D.&Keepers, G.A.(1988) Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey , D.&Christensen, A., eds. Psychopharmacology: Current Trends . Berlin: Springer-Verlag, pp. 74-93.
31. Chakraborty, N.&Johnston, T.(2004) Aripiprazole and neuroleptic malignant syndrome. International Clinical Psychopharmacology 19, 351-353.
32. Committee on Safety of Medicines(2004) Atypical antipsychotic drugs and stroke: message from Professor Gordon Duff, Chairman, Committee on Safety of medicines (CEM/ CMO/200401). Correll, C.U., Leucht, S.&Kane, J.M.(2004) Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of one year studies. American Journal of Psychiatry 161, 414-425.
33. Cox, B., Kerwin, R.&Lee, T.E.(1978) Dopamine receptors in the central thermoregulatory pathways of the rat. Journal of Physiology (London) 282, 471-483.
34. Day, J.C., Kinderman, P.&Bentall, R.(1998) A comparison of patients'and prescribers'beliefs about neuroleptic side - effects: prevalence, distress and causation. Acta Psychiatrica Scandinavica 97, 93-97.
35. Delay, J.&Deniker, P.(1968) Drug-induced extra-pyramidal syndromes. In: Vinken, P.S.&Bruyn, G.W., eds. Handbook of Clinical Neurology, Vol. 6. Diseases of the Basal Ganglia . New York: Elsevier North-Holland, pp. 248-266.
36. Delay, J., Pichot, P., Lempiere, T., Blissalde, B.&Peigne, F.(1960) Un neuroleptique majeur non phenothiazinique et non r é serpinique, l'halopéridol, dans le traitement des psychoses. Annals of Medical Psychology 18, 145-152.
37. Devinsky, O., Honigfeld, G.&Patin, J.(1991) Clozapine-related seizures. Neurology 41, 369-371.
38. Dixon, L., Weiden, P., Haag, G., Sweeney, J.&Frances, A.(1992) Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Comparative Psychiatry 33, 121-122.
39. Emsley, R., Turner, H.J., Schronen, J., Botha, K., Smit, R.&Oosthuizen, P.P.(2004) A single-blind randomised trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry 65, 696-701.
40. Farde, L., Nordstrom, A., Wiesel, F. et al.(1992) Positron emission tomographic analysis of central D1-dopamine and D2 - dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side - effects. Archives of General Psychiatry 49, 538-544.
41. Faurbye, A., Rasch, P., Bender Peterson, P., Brandenborg, G.&Pakkenberg, H.(1964) Neurological symptoms in the pharmacotherapy of psychoses. Acta Psychiatrica Scandinavica 40 , 10-26.
42. Food and Drug Administration(2003) Safety alert: RISPERDAL (risperidone). Washington, DC: US Food and Drug Administration; 1 Mar 2004. www.fda.gov/medwatch/ SAFETY/2003/risperdal.htm (accessed 15 Nov 2004).
43. Friedman, J.H., Feinberg, S.S.&Feldman, R.G.(1985) A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. Journal of the American Medical Association 254 , 2792-2795.
44. Ganzini, L., Casey, D., Hoffman, W.&Heintz, R.(1992) Tardive dyskinesia and diabetes mellitus. Psychopharmacology Bulletin 23, 281-286.
45. Gao, K., Kemp, D.E., Ganocy, S.J., Gajwani, P., Xia, G.&Calabrese, J.R.(2008). Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. Journal of Clinical Psychopharmacology 28 , 203-209.
46. Gardos, G.&Cole, J.(1997) Tardive dyskinesia and affective disorder , In: Yassa, R., Nair, N.&Jeste, D., eds. Neuroleptic - Induced Movement Disorders . Cambridge: Cambridge University Press, pp. 69-81.
47. Gardos, G., Cole, J., Salomon, M.&Schniebolk, S.(1987) Clinical forms of severe tardive dyskinesia. American Journal of Psychiatry 144, 895-902.
48. Gardos, G., Cole, J., Haskell, D. et al.(1988) The natural history of tardive dyskinesia. Journal of Clinical Psychopharmacology 8 (Suppl. 4), 31S-37S. Gardos, G., Casey, D.E., Cole, J.O. et al.(1994) Ten-year outcome of tardive dyskinesia. American Journal of Psychiatry 151 , 836-841.
49. Geddes, J., Freemantle, N., Harrison, P.&Bebbington, P.(2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 , 1371-1376.
50. Gill, S.S., Rochon, P.A., Herrmann, N. et al.(2005) Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. British Medical Journal 330 , 445-448.
51. Glazer, W., Naftolin, F., Moore, D.C., Bowers, M.B.&MacLusky , N.J.(1983) The relationship of circulating estradiol to tardive dyskinesia in men and post-menopausal women. Psychoneuroendocrinology 8, 429-434.
52. Gunne, L.&Haggstrom, J.(1985) Pathophysiology of tardive dyskinesia. Psychopharmacology 232, 191-193.
53. Guy, W.(1976) ECDEU Assessment Manual for Psychopharmacology (revised 1976), pp. 534-537. United Staes Government Printing Offi ce Washington, DC.
54. Haddad PM(1994) Neuroleptic malignant syndrome. May be caused by other drugs. BMJ 308, 200.
55. Haddad, P.M.&Sharma, S.G.(2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21, 911-936.
56. Hansen, L.(2001) A critical review of akathisia, and its possible association with suicidal behaviour. Human Psychopharmacology 16, 495-505.
57. Harrison-Woolrych, M.&Clark, D.W.J.(2004) Nose bleeds associated with use of risperidone. BMJ 328, 1416.
58. Hay, D., Hay, L., Blackwell, B.&Spiro, H.(1990) ECT and tardive dyskinesia. Journal of Geriatric Psychiatry and Neurology 3, 106-109.
59. Hermesh H, Aizenberg D, Weizman A(1987) A successful electroconvulsive treatment of neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica 75, 237-239.
60. Hermesh H, Aizenberg D, Lapidot M, Munitz H(1988) Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. American Journal of Psychiatry 145, 1431-1434.
61. Herrmann, N., Mamdani, M.&Lanctôt, K.L.(2004) Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry 161, 1113-1115.
62. Hughes, A.(1994) Botulinum toxin in clinical practice. Drugs 48 , 888-893.
63. Itil, T.&Soldatos, C.(1980) Epileptogenic side effects of psychotropic drugs. Journal of the American Medical Association 244 , 1460-1463.
64. Jeste, D., Caligiuri, M., Paulsen, J. et al.(1995) Risk of tardive dyskinesia in older patients. Archives of General Psychiatry 52 , 756-765.
65. Kane, J.&Smith, J.(1982) Tardive dyskinesia: prevalence and risk factors, 1959-79. Archives of General Psychiatry 39, 473-481.
66. Kane, J., Woerner, M., Weinhold, P. et al.(1984a) Incidence and severity of tardive dyskinesia in affective illness. In: Tardive Dyskinesia and Affective Illness . American Psychiatric Press , Washington, DC, pp. 22-28.
67. Kane, J., Woerner, M., Weinhold, P. et al.(1984b) Incidence of tardive dyskinesia: fi ve year data from a prospective study. Psychopharmacology Bulletin 20, 39-40.
68. Kane, J., Woerner, M., Borenstein, M., Wegner, J.&Lieberman , J.(1986) Integrating incidence and prevalence of tardive dyskinesia . Psychopharmacological Bulletin 22, 254-258.
69. Kane, J., Woerner, M.&Lieberman, J.(1988) Tardive dyskinesia: prevalence, incidence, and risk factors. Journal of Clinical Psychopharmacology 8(Suppl.), 52S-56S.
70. Kapur, S.&Seeman, P.(2001) Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. American Journal of Psychiatry 158, 360-369.
71. Kapur, S., Zipurski, R.&Remington, G.(1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry 156, 286-293.
72. Keepers, G.&Casey, D.(1987) Prediction of neuroleptic-induced dystonia. Journal of Clinical Psychopharmacology 7, 342-344.
73. Keepers, G.&Casey, D.(1991) Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. American Journal of Psychiatry 148, 85-89.
74. Keepers, G., Clappison, V.&Casey, D.(1983) Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry 40, 1113-1117.
75. Kinon, B.J., Jeste, D.V., Kollack-Walker, S., Stauffer, V.&Liu - Seifert, H.(2004) Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Progress in Neuropsychopharmacology Biological Psychiatry 28 , 985-996.
76. Klawans, H.&Rubovits, R.(1972) An experimental model of tardive dyskinesia. Journal of Neural Transmission 33 , 235-246.
77. Klawans, H.&Tanner, C.(1983) The reversibility of permanent tardive dyskinesia. Neurology 33(Suppl. 2), 163.
78. Kraepelin, E.(1907) Clinical Psychiatry . New York: MacMillan. Leo, R.(1996) Movement disorders associated with serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry 57 , 449-454.
79. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C.&Davis, J.M. (2009) Second-generation versus fi rst-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373 , 31-41.
80. Lieberman, J.A., Saltz, B.L., Johns, C.A., Pollack, S., Borenstein , M.&Kane, J.(1991) The effects of clozapine on tardive dyskinesia . British Journal of Psychiatry 58, 503-510.
81. Logothetis, J.(1967) Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 17, 869-877.
82. Mann, S.C.&Bolger, W.P.(1978) Psychotropic drugs, summer heat and humidity, and hyperpyrexia: a danger restated. American Journal of Psychiatry 135, 1097-1100.
83. Marsalek, M.(2000) Tardive drug-induced extrapyramidal syndromes . Pharmacopsychiatry 33, 14-33.
84. Mason, P.J., Morris, V.A.&Balcezak, T.J.(2000) Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 79, 201-209.
85. Mathews, T.&Aderibigbe, Y.A.(1999) Proposed research diagnostic criteria for neuroleptic malignant syndrome. International Journal of Neuropsychopharmacology 2, 129-144.
86. McCarron, M.M., Boettger, M.L.&Peck, J.I.(1992) A case of neuroleptic malignant syndrome successfully treated with amantadine. Journal of Clinical Psychiatry 43, 381-382.
87. McCreadie, R.G., Thara, R., Kamath, S. et al.(1996). Abnormal movements in never-medicated Indian patients with schizophrenia . British Journal of Psychiatry 168, 221-226.
88. Messing, R.O., Closson, R.G.&Simon, R.P.(1984) Drug-induced seizures: a 10 year experience. Neurology 17, 869-877.
89. Miller, C.H.&Fleischhacker, W.W.(2000) Managing antipsychotic-induced acute and chronic akathisia. Drug Safety 22, 73-81.
90. Mitra, S.&Haddad, P.M.(2007) Documentation of extrapyramidal symptoms. Psychiatric Bulletin 31, 76-77.
91. Morgenstern, H.&Glazer, W.(1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Archives of General Psychiatry 50 , 723-733.
92. Murray, C.J., Lopez, A.D.(1996) The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA, Harvard School of Public Health, (Global Burden of Disease and Injury Series, vol. I), 1996.
93. National Institute for Clinical Excellence(2009) Core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical Guideline 82. March 2009. London: NICE. www.nice.org.uk
94. Newton-John, H.(1988) Acute upper airway obstruction due to supraglottic dystonia induced by a neuroleptic. BMJ 297 , 964-965.
95. Norton, J.(2001) Laryngeal dystonia in psychiatry. Canadian Journal of Psychiatry 46, 453.
96. Ojemann, L.M., Baugh-Bookman, C.&Dudley, D.L.(1987) Effect of psychotropic medications on seizure control in patients with epilepsy. Neurology 37, 1525-1527.
97. Olmsted, T.R.(1998) Neuroleptic malignant syndrome: guidelines for treatment and reinstitution of neuroleptics. South Medical Journal 81, 888-891.
98. Pandurangi, A.&Aderibigbe, Y.(1995) Tardive dyskinesia in non-western countries: a review. European Archives of Psychiatry and Clinical Neuroscience 246, 47-52.
99. Pappa, S.&Dazzan, P.(2008) Spontaneous movement disorders in antipsychotic-naive patients with fi rst-episode psychoses: a systematic review. Psychological Medicine 12, 1-12.
100. Pehek, E.(1996) Local infusion of the serotonin antagonist ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. Synapse 24, 12-18
101. Pope, H.G., Keck, P.E.&McElroy, S.L.(1986) Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry 143 , 1227-1233.
102. Quitkin, F., Rifkin, A., Gochfeld, L.&Klein, D.(1977) Tardive dyskinesia: are fi rst signs reversible? American Journal of Psychiatry 134, 84-87.
103. Rajput, A., Rozdilsky, B., Hornykiewicz, O. et al.(1982) Reversible drug-induced parkinsonism: clinicopathologic study of two cases. Archives of Neurology 39, 644-646.
104. Reulbach, U., Dütsch, C., Biermann, T. et al.(2007) Managing an effective treatment for neuroleptic malignant syndrome. Critical Care 11, R4.
105. Richardson, M.&Craig, T.(1982) The coexistence of parkinsonism-like symptoms and tardive dyskinesia. American Journal of Psychiatry 139, 341-343.
106. Richardson, M., Haugland, M., Pass, R.&Craig, T.(1986) The prevalence of tardive dyskinesia in a mentally retarded population . Psychopharmacological Bulletin 22, 243-249.
107. Richardson, M., Suckow, R., Whittaker, R. et al.(1989) The plasma phenylalanine/large neutral amino acid ratio: a risk factor for tardive dyskinesia. Psychopharmacological Bulletin 25 , 47-51.
108. Rosebush, P.I., Stewart, T.D.&Gelenberg, A.J.(1989) Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. Journal of Clinical Psychiatry 50 , 295-298.
109. Sachdev, P.(2000) The current status of tardive dyskinesia. Australian and New Zealand Journal of Psychiatry 34, 355-369.
110. Saltz, B.L., Woerner, M.G., Kane, J.M. et al.(1991) Prospective study of tardive dyskinesia incidence in the elderly. Journal of the American Medical Association 266, 2402-2406.
111. Schlichther, W., Bristow, M.E., Schultz, S.&Henderson, A.C. (1956) Seizures occurring during intensive chlorpromazine therapy. Canadian Medical Association Journal 74, 364-366.
112. Schneider, L.S., Dagerman, K.S.&Insel, P.(2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294, 1934-1943.
113. Schneider, L.S., Dagerman, K.&Insel, P.S.(2006a) Effi cacy and adverse effects of atypical antipsychotics for dementia: meta - analysis of randomized, placebo-controlled trials. Amerian Journal of Geriatric Psychiatry 14, 191-210.
114. Schneider, L.S., Tariot, P.N., Dagerman, K.S. et al.(2006b) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine 355 , 1525-1538.
115. Schonecker, M.(1957) Ein eigentumliches Syndrom im oralen Bereich bei Megaphenapplikation. Nervenaerzt 28, 35-36.
116. Shalev, A., Hermesh, H.&Munitz, H.(1989) Mortality from neuroleptic malignant syndrome. Journal of Clinical Psychiatry 50, 18-25.
117. Sigwald, J., Bouttier, D.&Raymondeaud, C.(1959) Quatre cas de dyskinesie facio-bucco-lingua-masticatrice a l'evolution prolongee secondaire a un traitment par les neuroleptiques. Revue Neurologique 100, 751-755.
118. Singh, H., Levinson, D.F., Simpson, G.M., Lo, E.S.&Friedman , E.(1990) Acute dystonia during fi xed-dose neuroleptic treatment . Journal of Clinical Psychopharmacology 10, 389-396.
119. Smith, J.&Baldessarini, R.(1980) Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry 37, 1368-1373.
120. Smith, D.A.&Beier, M.T.(2004) Association between risperidone treatment and cerebrovascular adverse events: examining the evidence and postulating hypotheses for an underlying mechanism. Journal of the American Medical Directors Association 5, 129-132.
121. Spivak, B., Mester, R., Abesgaus, J. et al.(1997) Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. Journal of Clinical Psychiatry 58, 318-322.
122. Sramek, J., Simpson, G., Morrison, R.&Heiser, J.(1986) Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. Journal of Clinical Psychiatry 47, 305-309.
123. Stones, M., Kennie, D.C.&Fulton, J.D.(1990) Dystonic dysphagia associated with fl uspirilene. BMJ 301, 668-669.
124. Susman, V.L.(2001) Clinical management of neuroleptic malignant syndrome. Psychiatric Quarterly 72, 325-336.
125. Swett, C.(1975) Drug-induced dystonia. American Journal of Psychiatry 132, 532-534.
126. Tarsy, D., Kaufman, D., Sethi, K.D., Rivner, M.H., Molho, E.&Factor, S.(1997) An open-label study of botulinum toxin A for treatment of tardive dystonia. Clinical Neuropharmacology 20 , 90-93.
127. Tauscher, J., Kufferle, B., Asenbaum, S. et al.(1999) In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology (Berlin) 141, 175-181.
128. Taylor, D., Paton, C.&Kerwin, R.(2007) The Maudsley Prescribing Guidelines , 9th edn. South London and Maudsley NHS Foundation Trust&Oxleas NHS Foundation Trust, Informa Healthcare. Uhrbrand, L.&Faurbye, A.(1960) Reversible and irreversible dyskinesia after treatment with perphenazine, chloropromazine, reserpine, and electroconvulsive therapy. Psychopharmacoligia 1, 408-418.
129. van Harten, P.N.&Kahn, R.S.(1999) Tardive dystonia. Schizophrenia Bull e tin 25, 741-748.
130. van Os, J., Fahy, T., Jones, P. et al.(1997) Tardive dyskinesia: who is at risk? Acta Psychiatrica Scandinavica 96, 206-216.
131. Vinson, D.R.(2004) Diphenhydramine in the treatment of akathisia induced by prochlorperazine. Journal of Emergency Medicine 26, 265-270.
132. Waddington, J., Youssef, H., Dolphin, C.&Kinsella, A.(1987) Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Archives of General Psychiatry 44 , 907-912.
133. Waddington, J.L., O'Callaghan, E., Larkin, C.&Kinsella, A. (1993) Cognitive dysfunction in schizophrenia: organic vulnerability factor or state marker for tardive dyskinesia? Brain and Cognition 23, 56-70.
134. Wang, Y., Turnbull, I., Calne, S., Stoessl, A.&Calne, D.(1997) Pallidotomy for tardive diskinesia. Lancet 349, 777-778.
135. Wang P.S., Schneeweiss S., Avorn J. et al.(2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications . New England Journal of Medicine 353, 2335-2341.
136. Weetman, J., Anderson, I., Gregory, R.&Gill, S.(1997) Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia [letter ]. Journal of Neurology, Neurosurgery, and Psychiatry 63, 554-556.
137. Weiden, P.J., Mann, J.J., Haas, G., Mattson, M.&Frances, A. (1987) Clinical non-recognition of neuroleptic-induced movement disorders: a cautionary study. American Journal of Psychiatry 144, 1148-1153.
138. Weller, M.(1992) NMS and lethal catatonia. Journal of Clinical Psychiatry 53, 294.
139. White, D.A.C.(1992) Catatonia and the neuroleptic malignant syndrome: a single entitity? British Journal of Psychiatry 161 , 558-560.
140. White, D.A.C.&Robins, A.H.(1991) Catatonia: harbinger of the neuroleptic syndrome. British Journal of Psychiatry 158 , 419-421.
141. Youssef, H.&Waddington, J.(1987) Mortality and morbidity in tardive dyskinesia: association in chronic schizophrenia. Acta Psychiatrica Scandinavica 75, 74-77.
142. Zoleptil Summary of Product Characteristics (2002) Newbury: Orion Pharma (UK) Ltd